Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
Status:
Unknown status
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Objective 1: To advance the investigators understanding on the effect of solifenacin
succinate (10 mg OD) vs. fesoterodine (8mg OD) on urinary urgency using a validated Urgency
Severity and Impact Questionnaire (USIQ).
Hypothesis 1.1: The severity of urgency symptoms as measured by USIQ will change differently
in women with OAB following a 3 month treatment with solifenacin succinate (10 mg OD) vs.
fesoterodine (8mg OD).
Hypothesis 2.1: Condition-specific quality of life (QOL) as measured by USIQ will change
differently in women with OAB following a 3 month treatment with solifenacin succinate (10 mg
OD) vs. fesoterodine (8mg OD).
Objective 2: To advance the investigators understanding on the adverse events (AE's) of
solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Hypothesis 1.1: The severity and rate of AE's in women with OAB following a 3 month of
treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD) will be different.